Indivior Pharmaceuticals, Inc.— Sankey Diagram
Annual mode · period ending 2026-03-31 · SEC EDGAR
FY2026 - Q4(Jan 26 · Feb 26 · Mar 26)
Total Assets
$1.20B
↓-12.9% -$178Mvs FY2025
Total Liabilities
$1.34B
↓-19.2% -$319Mvs FY2025
Cash
$175M
↓-53.0% -$197Mvs FY2025
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2026 | FY2025 |
|---|---|---|
| Total Assets | $1.20B | $1.38B |
| Current Assets | $667M | $883M |
| Cash | $175M | $372M |
| ST Investments | $0 | $1M |
| Receivables | $273M | $243M |
| Inventory | $152M | $163M |
| Other Current | $67M | $104M |
| Non-Current Assets | $530M | $492M |
| PPE | $157M | $104M |
| Goodwill | $0 | $0 |
| Intangibles | $0 | $0 |
| Investments | $27M | $27M |
| Other Non-Current | $346M | $361M |
| Total Liab+Eq | $1.20B | $1.38B |
| Current Liab. | $779M | $1.00B |
| Accounts Payable | $35M | $46M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $744M | $959M |
| Non-Current Liab. | $562M | $655M |
| Long-Term Debt | $486M | $311M |
| Other LT Liab. | $76M | $344M |
| Equity | $-144M | $-285M |
| Retained Earnings | $280M | $406M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · INDV · Comparing FY2026 vs FY2025